Octapharma’s Hemophilia A Drug Approved By European Commission

Another hemophilia option will soon be available to the masses in Europe. According to the website Pharmaceutical Processing, the European Commission has officially published approval of pharmaceutical company Octapharma’s Nuwiq  for the treatment and prophylaxis of bleeding in all age groups with hemophilia A.

Nuwiq is the newest generation of FVIII replacement combined with the von Willebrand coagulation factor, both of which are potentially important properties in reducing FVIII inhibitor formation, which can be a major setback for any hemophiliac when medicating their doses of factor. The drug’s development is aimed to address the challenges of inhibitor formation as well as the frequent infusions required for prophylaxis of bleeding.

Olaf Walter, MD, PhD, MBA, Senior Vice President of International Business Units, said the following about Nuwiq: “It represents a potential leap forward in dealing with the greatest clinical challenges in hemophilia A – FVIII inhibitors and the frequent infusions needed for bleeding prophylaxis. In clinical trials, Nuwiq ® demonstrated outstanding efficacy in preventing and treating bleeding in patients previously on FVIII (PTPs). No inhibitors in clinical trials in PTPs have been seen.”

Continuous and current data for Nuwiq has been submitted to authorities in Canada, the United States, and Australia, with further worldwide submissions planned. WeBleed will publish more information on Nuwiq as it becomes available.

Photo Credit – Octapharma

webleed.org – your source for bleeding news!